Update of the drug resistance mutations in HIV-1: March 2013.
V. Johnson, V. Calvez, H. Gunthard, R. Paredes, D. Pillay, R. Shafer, A. Wensing, D. Richman
2013.2.1Topics in Antiviral Medicine
tlooto Summary
2 integrase strand transfer inhibitors (InSTIs), elvitegra-vir and dolutegravir, have become available and were added to the treatment of HIV-1 treat-ment-naive patients.
Abstract
In this update, 2 integrase strand transfer inhibitors (InSTIs), elvitegra-vir and dolutegravir, have become available and were added to the fig-ure. Elvitegravir was approved by the US Food and Drug Administration (FDA) in August 2012 for HIV-1 treat-ment-naive patients as part of a fixed-dose combination of elvitegravir/ cobicistat/tenofovir/emtricitabine.
Citation format
JOHNSON, V., et al. Update of the drug resistance mutations in HIV-1: March 2013. Topics in Antiviral Medicine, 2013, 21 1: 6–14.